The Technical Analyst
Hepion Pharmaceuticals [HEPA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Hepion Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.10% $1.330
America/New_York / 26 apr 2024 @ 09:43
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.28 mill |
| EPS: | -12.32 |
| P/E: | -0.110 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 5.47 mill |
| Avg Daily Volume: | 0.0779 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.110 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.110 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.67 (176.02%) $2.34 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.009 - 1.557 ( +/- 21.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Purcell Michael J. | Buy | 50 000 | Restricted Stock Units |
| 2024-03-05 | Purcell Michael J. | Buy | 0 | |
| 2024-02-19 | Block Timothy M. | Buy | 85 000 | Stock Options |
| 2024-02-19 | Jacob Gary S | Buy | 85 000 | Stock Options |
| 2024-02-19 | Lbiati Kaouthar | Buy | 85 000 | Stock Options |
| INSIDER POWER |
|---|
| 93.13 |
| Last 96 transactions |
| Buy: 8 825 675 | Sell: 984 166 |
Forecast:
11:22 - $1.239
Live Trading Signals (every 1 min)
Forecast
1: 09:52 - $1.296
Forecast 2: 10:42 - $1.282
Forecast 3: 11:22 - $1.239
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.330 (3.10% ) |
| Volume | 0.0025 mill |
| Avg. Vol. | 0.0779 mill |
| % of Avg. Vol | 3.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HEPA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HEPA
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-04-19 16:30:00 - Press Release
Hepion Pharmaceuticals Initiates Wind-down Activities In Phase 2b ‘ascend-nash' Trial
Edison, n.j., april 19, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ascend-nash trial, while continuing to explore strategic alternatives, as previously announced in december 2023.
2024-03-06 08:30:00 - Press Release
Hepion Pharmaceuticals Strengthens Board Of Directors With Appointment Of Michael Purcell
Edison, n.j., march 06, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, and other chronic diseases, today announced the appointment of michael purcell to the company's board of directors, effective march 5, 2024.
2024-02-16 08:00:00 - Press Release
Hepion Pharmaceuticals Announces Exercise Of Warrants For Approximately $2.0 Million Aggregate Gross Proceeds
Edison, n.j., feb. 16, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding series b common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of hepion common stock for gross proceeds to the company of approximately $2.0 million.
2024-01-03 17:15:00 - Press Release
Hepion Pharmaceuticals To Present At Nash-tag 2024
Edison, n.j., jan. 03, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 nash-tag conference, which is being held january 4-6, 2024, in park city, utah.
2023-12-07 08:00:00 - Press Release
Hepion Pharmaceuticals Announces Restructuring Plan To Enhance Shareholder Value And Management Changes
Restructuring program purpose is to preserve capital and optimize clinical development program management plans to continue to evaluate its phase 2b ascend-nash clinical trial taking in account current market environment cash runway extended into q2 2025 edison, n.j., dec. 07, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that its board of directors has approved a strategic restructuring plan with the objective of preserving capital by initially reducing operating costs by approximately 60% going forward.
Latest News
2024-04-22 08:56:18 - InvestorPlace
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is diving on Monday after the biopharmaceutical company announced plans to wind down a clinical trial. A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study.
2024-01-03 17:15:00 - GlobeNewsWire
Hepion Pharmaceuticals to Present at NASH-TAG 2024
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.
2023-11-28 16:15:00 - GlobeNewsWire
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.
2023-11-10 08:50:00 - GlobeNewsWire
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat
Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023 Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023
2023-09-21 16:05:00 - GlobeNewsWire
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Chief Executive Officer, Robert Foster, PharmD, PhD, will participate in a panel discussion during the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 9:45 a.m. ET in NYC.
2023-06-15 16:45:00 - GlobeNewsWire
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution –
2023-05-24 13:13:32 - Zacks Investment Research
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.
2023-05-23 05:02:33 - Invezz
HEPA stock price surged but beware of this glaring Hepion risk
Hepion Pharmaceuticals' (NASDAQ: HEPA) stock price went parabolic on Monday after the company made an important announcement about its mid-stage trial. The shares jumpd by more than 110% and reached a high of $19.66, the highest level since January 17.
2023-05-22 08:19:52 - InvestorPlace
Why Is Hepion Pharmaceuticals (HEPA) Stock Up 68% Today?
Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is rising higher on Monday as the company prepares to cover clinical trial results. Hepion Pharmaceuticals is holding a conference call at 8:30 a.m.
2023-05-19 16:05:00 - GlobeNewsWire
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial before the market opens on Monday, May 22, 2023.